Possible effects of chemokine-like factor-like MARVEL transmembrane domain-containing family on antiphospholipid syndrome.
Journal
Chinese medical journal
ISSN: 2542-5641
Titre abrégé: Chin Med J (Engl)
Pays: China
ID NLM: 7513795
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
pubmed:
5
4
2021
medline:
19
8
2021
entrez:
4
4
2021
Statut:
epublish
Résumé
Antiphospholipid syndrome (APS) is a systemic autoimmune disease defined by thrombotic or obstetrical events and persistent antiphospholipid antibodies (aPLs). Chemokine-like factor-like MARVEL transmembrane domain-containing family (CMTM) is widely expressed in the immune system and may closely related to APS. This review aimed to systematically summarize the possible effects of CMTM on APS. Publications were collected from PubMed and Web of Science databases up to August 2020. CKLF, CKLFSF, CMTM, antiphospholipid syndrome, immune cells, and immune molecules were used as search criteria. Immune cells, including neutrophil, dendritic cells (DCs), T-cells, B-cells, and inflammatory cytokines, play an important role in the development of APS. Chemokine-like factor 1 (CKLF1) has a chemotactic effect on many cells and can affect the expression of inflammatory cytokines and adhesion molecules through the nuclear factor-kB (NF-kB) pathway or mitogen-activated protein kinase (MARK) pathway. CKLF1 can participate in the maturation of DCs, T lymphocyte activation, and the activation of neutrophils through the MAPK pathway. CMTM1 may act on Annexin A2 by regulating Ca2+ signaling. CMTM2 and CMTM6 are up-regulated in neutrophils of APS patients. Some CMTM family members influence the activation and accumulation of platelets. CMTM3 and CMTM7 are binding partners of B-cell linker protein (BLNK), thereby linking B cell receptor (BCR) and activating BLNK-mediated signal transduction in B cells. Moreover, CMTM3 and CMTM7 can act on DCs and B-1a cell development, respectively. CMTM may have potential effects on the development of APS by acting on immune cells and immune molecules. Thus, CMTM may act as a novel prognostic factor or immunomodulatory treatment option of APS.
Identifiants
pubmed: 33813507
doi: 10.1097/CM9.0000000000001449
pii: 00029330-202107200-00004
pmc: PMC8318642
doi:
Substances chimiques
CMTM7 protein, human
0
Chemokines
0
Cytokines
0
MARVEL Domain-Containing Proteins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1661-1668Informations de copyright
Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.
Références
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295–306. doi: 10.1111/j.1538-7836.2006.01753.x.
doi: 10.1111/j.1538-7836.2006.01753.x
van den Hoogen LL, van Roon JAG, Radstake TRDJ, Fritsch-Stork RDE, Derksen RHWM. Delineating the deranged immune system in the antiphospholipid syndrome. Autoimmun Rev 2016; 15:50–60. doi: 10.1016/j.autrev.2015.08.011.
doi: 10.1016/j.autrev.2015.08.011
Han W, Ding P, Xu M, Wang L, Rui M, Shi S, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics 2003; 81:609–617. doi: 10.1016/s0888-7543(03)00095-8.
doi: 10.1016/s0888-7543(03)00095-8
Lu J, Wu QQ, Zhou YB, Zhang KH, Pang BX, Li L, et al. Cancer research advance in CKLF-like MARVEL transmembrane domain containing member family (Review). Asian Pac J Cancer Prev 2016; 17:2741–2744.
Yang GY, Chen X, Sun YC, Ma CL, Qian G. Chemokine-like factor 1 (CLFK1) is over-expressed in patients with atopic dermatitis. Int J Biol Sci 2013; 9:759–765. doi: 10.7150/ijbs.6291.
doi: 10.7150/ijbs.6291
Han W, Lou Y, Tang J, Zhang Y, Chen Y, Li Y, et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J 2001; 357:127–135. doi: 10.1042/0264-6021:3570127.
doi: 10.1042/0264-6021:3570127
Zhong J, Wang Y, Qiu X, Mo X, Liu Y, Li T, et al. Characterization and expression profile of CMTM3/CKLFSF3. J Biochem Mol Biol 2006; 39:537–545. doi: 10.5483/bmbrep.2006.39.5.537.
doi: 10.5483/bmbrep.2006.39.5.537
Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res 2009; 69:5194–5201. doi: 10.1158/0008-5472.CAN-08-3694.
doi: 10.1158/0008-5472.CAN-08-3694
Li H, Guo X, Shao L, Plate M, Mo X, Wang Y, et al. CMTM5-v1, a four-transmembrane protein, presents a secreted form released via a vesicle-mediated secretory pathway. BMB Rep 2010; 43:182–187. doi: 10.5483/bmbrep.2010.43.3.182.
doi: 10.5483/bmbrep.2010.43.3.182
Wang L, Wu C, Zheng Y, Qiu X, Wang L, Fan H, et al. Molecular cloning and characterization of chemokine-like factor super family member 1 (CKLFSF1), a novel human gene with at least 23 alternative splicing isoforms in testis tissue. Int J Biochem Cell Biol 2004; 36:1492–1501. doi: 10.1016/j.biocel.2003.11.017.
doi: 10.1016/j.biocel.2003.11.017
Gao DH, Hu H, Fang ZW, Huo F, Wang HR, Xu KX, et al. Research advances in chemokine-like factor super family member 8 (In Chinese). Acta Acad Med Sin 2016; 38:746–749. doi: 10.3881/j.issn.1000-503X.2016.06.021.
doi: 10.3881/j.issn.1000-503X.2016.06.021
Wu K, Li X, Gu H, Yang Q, Liu Y, Wang L. Research advances in CKLF-like MARVEL transmembrane domain-containing family in non-small cell lung cancer. Int J Biol Sci 2019; 15:2576–2583. doi: 10.7150/ijbs.33733.
doi: 10.7150/ijbs.33733
Duan HJ, Li XY, Liu C, Deng XL. Chemokine-like factor-like MARVEL transmembrane domain-containing family in autoimmune diseases. Chin Med J 2020; 133:951–958. doi: 10.1097/CM9.0000000000000747.
doi: 10.1097/CM9.0000000000000747
Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368:1033–1044. doi: 10.1056/NEJMra1112830.
doi: 10.1056/NEJMra1112830
Firestein GS, Gabriel SE, McInnes IB, O’Dell JR. Kelley and Firestein's textbook of rheumatology, 10th edn. Philadelphia, PA: Elsevier; 2017.
Lutters BCH, Derksen RHWM, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2’. J Biol Chem 2003; 278:33831–33838. doi: 10.1074/jbc.M212655200.
doi: 10.1074/jbc.M212655200
Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, Papalardo E, Vargas G, Deora AB, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009; 114:3074–3083. doi: 10.1182/blood-2008-11-188698.
doi: 10.1182/blood-2008-11-188698
van Lummel M, Pennings MTT, Derksen RH, Urbanus RT, Lutters BC, Kaldenhoven N, et al. The binding site in {beta}2-glycoprotein I for ApoER2’ on platelets is located in domain V. J Biol Chem 2005; 280:36729–36736. doi: 10.1074/jbc.M504172200.
doi: 10.1074/jbc.M504172200
Erkan D, Lockshin MD. What is antiphospholipid syndrome? Curr Rheumatol Rep 2004; 6:451–457. doi: 10.1007/s11926-004-0024-1.
doi: 10.1007/s11926-004-0024-1
Zuo Y, Shi H, Li C, Knight JS. Antiphospholipid syndrome: a clinical perspective. Chin Med J 2020; 133:929–940. doi: 10.1097/CM9.0000000000000705.
doi: 10.1097/CM9.0000000000000705
Bordron A, Dueymes M, Levy Y, Jamin C, Ziporen L, Piette JC, et al. Anti-endothelial cell antibody binding makes negatively charged phospholipids accessible to antiphospholipid antibodies. Arthritis Rheum 1998; 41:1738–1747. doi: 10.1002/1529-0131(199810)41:10<1738::AID-ART6>3.0.CO;2-7.
doi: 10.1002/1529-0131(199810)41:10
Font J, Espinosa G, Tassies D, Pino M, Khamashta MA, Gallart T, et al. Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. Arthritis Rheum 2002; 46:3283–3289. doi: 10.1002/art.10634.
doi: 10.1002/art.10634
Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: A pathway to targeted therapies. Thromb Res 2004; 114:467–476. doi: 10.1016/j.thromres.2004.06.031.
doi: 10.1016/j.thromres.2004.06.031
Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B, Reber G, Kruithof EKO. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost 2002; 88:851–857.
Mak IYH, Brosens JJ, Christian M, Hills FA, Chamley L, Regan L, et al. Regulated expression of signal transducer and activator of transcription, Stat5, and its enhancement of PRL expression in human endometrial stromal cells in vitro. J Clin Endocrinol Metab 2002; 87:2581–2588. doi: 10.1210/jcem.87.6.8576.
doi: 10.1210/jcem.87.6.8576
Garcia D, Erkan D. Diagnosis and management of the Antiphospholipid syndrome. N Engl J Med 2018; 378:2010–2021. doi: 10.1056/NEJMra1705454.
doi: 10.1056/NEJMra1705454
Broder A, Chan JJ, Putterman C. Dendritic cells: An important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases. Clin Immunol 2013; 146:197–206. doi: 10.1016/j.clim.2012.12.002.
doi: 10.1016/j.clim.2012.12.002
Kahn P, Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 2008; 58:2824–2834. doi: 10.1002/art.23764.
doi: 10.1002/art.23764
Scheu S, Ali S, Ruland C, Arolt V, Alferink J. The C-C chemokines CCL17 and CCL22 and their receptor CCR4 in CNS autoimmunity. Int J Mol Sci 2017; 18:2306doi: 10.3390/ijms18112306.
doi: 10.3390/ijms18112306
Imai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R, et al. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J Biol Chem 1998; 273:1764–1768. doi: 10.1074/jbc.273.3.1764.
doi: 10.1074/jbc.273.3.1764
Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem 1997; 272:15036–15042. doi: 10.1074/jbc.272.23.15036.
doi: 10.1074/jbc.272.23.15036
Wang Y, Zhang Y, Yang X, Han W, Liu Y, Xu Q, et al. Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4). Life Sci 2006; 78:614–621. doi: 10.1016/j.lfs.2005.05.070.
doi: 10.1016/j.lfs.2005.05.070
Wang Y, Zhang Y, Han W, Li D, Tian L, Yin C, et al. Two C-terminal peptides of human CKLF1 interact with the chemokine receptor CCR4. Int J Biochem Cell Biol 2008; 40:909–919. doi: 10.1016/j.biocel.2007.10.028.
doi: 10.1016/j.biocel.2007.10.028
Andre P, Boretto J, Hueber AO, Regnier-Vigouroux A, Gorvel JP, Ferrier P, et al. A dominant-negative mutant of the Rab5 GTPase enhances T cell signaling by interfering with TCR down-modulation in transgenic mice. J Immunol 1997; 159:5253–5263.
Hoogeboom R, Tolar P. Molecular mechanisms of B cell antigen gathering and endocytosis. Curr Top Microbiol Immunol 2016; 393:45–63. doi: 10.1007/82_2015_476.
doi: 10.1007/82_2015_476
Yuan W, Liu B, Wang X, Li T, Xue H, Mo X, et al. CMTM3 decreases EGFR expression and EGF-mediated tumorigenicity by promoting Rab5 activity in gastric cancer. Cancer Lett 2017; 386:77–86. doi: 10.1016/j.canlet.2016.11.015.
doi: 10.1016/j.canlet.2016.11.015
Plate M, Li T, Wang Y, Mo X, Zhang Y, Ma D, et al. Identification and characterization of CMTM4, a novel gene with inhibitory effects on HeLa cell growth through Inducing G2/M phase accumulation. Mol Cells 2010; 29:355–361. doi: 10.1007/s10059-010-0038-7.
doi: 10.1007/s10059-010-0038-7
Li T, Guo XH, Wang Y, Markus P, Shao LN, Song QS, et al. Preparation, purification and characterization of the polyclonal antibody against human CMTM4 (in Chinese). Chin J Cell Mol Immunol 2008; 24:41–44.
Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52:1545–1554. doi: 10.1002/art.21009.
doi: 10.1002/art.21009
Ke X, Jia L, Jing H, Liu Y, Zhang Y, Di C. Effects of novel human chemokine-like factor 1 (CKLF1) on bone marrow hematopoietic stem cell/progenitor cell in vitro (in Chinese). Chin J Hematol 2002; 23:301–303.
Kong LL, Wang ZY, Han N, Zhuang XM, Wang ZZ, Li H, et al. Neutralization of chemokine-like factor 1, a novel C-C chemokine, protects against focal cerebral ischemia by inhibiting neutrophil infiltration via MAPK pathways in rats. J Neuroinflammation 2014; 11:112doi: 10.1186/1742-2094-11-112.
doi: 10.1186/1742-2094-11-112
Chrifi I, Louzao-Martinez L, Brandt M, van Dijk C, Burgisser P, Zhu C, et al. CMTM3 (CKLF-like marvel transmembrane domain 3) mediates angiogenesis by regulating cell surface availability of VE-cadherin in endothelial adherens junctions. Arterioscler Thromb Vasc Biol 2017; 37:1098–1114. doi: 10.1161/ATVBAHA.116.308792.
doi: 10.1161/ATVBAHA.116.308792
Montiel-Manzano G, Romay-Penabad Z, Papalardo DME, Meillon-Garcia LA, Garcia-Latorre E, Reyes-Maldonado E, et al. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann N Y Acad Sci 2007; 1108:540–553. doi: 10.1196/annals.1422.057.
doi: 10.1196/annals.1422.057
Keith JC Jr, Albert LM, Leathurby Y, Follettie M, Wang L, Borges-Marcucci L, et al. The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther 2005; 7:R427–R438.doi: 10.1186/ar1692.
doi: 10.1186/ar1692
Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002; 82:331–371. doi: 10.1152/physrev.00030.2001.
doi: 10.1152/physrev.00030.2001
Dias IDSR, Mok SWF, Gordillo-Martinez F, Khan I, Hsiao WWL, Law BYK, et al. The calcium-induced regulation in the molecular and transcriptional circuitry of human inflammatory response and autoimmunity. Front Pharmacol 2017; 8:962doi: 10.3389/fphar.2017.00962.
doi: 10.3389/fphar.2017.00962
Wong VKW, Qiu C, Xu SW, Law BYK, Zeng W, Wang H, et al. Ca2+ signalling plays a role in celastrol-mediated suppression of synovial fibroblasts of rheumatoid arthritis patients and experimental arthritis in rats. Br J Pharmacol 2019; 176:2922–2944. doi: 10.1111/bph.14718.
doi: 10.1111/bph.14718
Cao L, Yang C, Zhu B, Zhang G, Zhao N, Liu X, et al. A novel protein CMTM1-v5 specifically induced human lymphoma cells apoptosis in vitro and in vivo. Exp Cell Res 2019; 385:111623doi: 10.1016/j.yexcr.2019.111623.
doi: 10.1016/j.yexcr.2019.111623
Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002; 87:518–522. doi: 10.1055/s-0037-1613033.
doi: 10.1055/s-0037-1613033
Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood 2014; 124:611–622. doi: 10.1182/blood-2014-02-554980.
doi: 10.1182/blood-2014-02-554980
Rowley JW, Oler AJ, Tolley ND, Hunter BN, Low EN, Nix DA, et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 2011; 118:e101–e111. doi: 10.1182/blood-2011-03-339705.
doi: 10.1182/blood-2011-03-339705
Sim DS, Dilks JR, Flaumenhaft R. Platelets possess and require an active protein palmitoylation pathway for agonist-mediated activation and in vivo thrombus formation. Arterioscler Thromb Vasc Biol 2007; 27:1478–1485. doi: 10.1161/ATVBAHA.106.139287.
doi: 10.1161/ATVBAHA.106.139287
Dowal L, Yang W, Freeman MR, Steen H, Flaumenhaft R. Proteomic analysis of palmitoylated platelet proteins. Blood 2011; 118:e62–e73. doi: 10.1182/blood-2011-05-353078.
doi: 10.1182/blood-2011-05-353078
Lood C, Amisten S, Gullstrand B, Jönsen A, Allhorn M, Truedsson L, et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: Up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 2010; 116:1951–1957. doi: 10.1182/blood-2010-03-274605.
doi: 10.1182/blood-2010-03-274605
Shao L, Li T, Mo X, Majdic O, Zhang Y, Seyerl M, et al. Expressional and functional studies of CKLF1 during dendritic cell maturation. Cell Immunol 2010; 263:188–195. doi: 10.1016/j.cellimm.2010.03.015.
doi: 10.1016/j.cellimm.2010.03.015
Imamura Y, Katahira T, Kitamura D. Identification and characterization of a novel BASH N terminus-associated protein, BNAS2. J Biol Chem 2004; 279:26425–26432. doi: 10.1074/jbc.M403685200.
doi: 10.1074/jbc.M403685200
Miyazaki A, Yogosawa S, Murakami A, Kitamura D. Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor. PLoS One 2012; 7:e31829doi: 10.1371/journal.pone.0031829.
doi: 10.1371/journal.pone.0031829
Meng H, Yalavarthi S, Kanthi Y, Mazza LF, Elfline MA, Luke CE, et al. In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis. Arthritis Rheumatol 2017; 69:655–667. doi: 10.1002/art.39938.
doi: 10.1002/art.39938
Maddahi A, Ansar S, Chen Q, Edvinsson L. Blockade of the MEK/ERK pathway with a raf inhibitor prevents activation of pro-inflammatory mediators in cerebral arteries and reduction in cerebral blood flow after subarachnoid hemorrhage in a rat model. J Cereb Blood Flow Metab 2011; 31:144–154. doi: 10.1038/jcbfm.2010.62.
doi: 10.1038/jcbfm.2010.62
Benakis C, Bonny C, Hirt L. JNK inhibition and inflammation after cerebral ischemia. Brain Behav Immun 2010; 24:800–811. doi: 10.1016/j.bbi.2009.11.001.
doi: 10.1016/j.bbi.2009.11.001
Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005; 1754:253–262. doi: 10.1016/j.bbapap.2005.08.017.
doi: 10.1016/j.bbapap.2005.08.017
Knight JS, Meng H, Coit P, Yalavarthi S, Sule G, Gandhi AA, et al. Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. JCI Insight 2017; 2:e93897doi: 10.1172/jci.insight.93897.
doi: 10.1172/jci.insight.93897
Clark-Lewis I, Kim KS, Rajarathnam K, Gong JH, Dewald B, Moser B, et al. Structure-activity relationships of chemokines. J Leukoc Biol 1995; 57:703–711. doi: 10.1002/jlb.57.5.703.
doi: 10.1002/jlb.57.5.703
Li T, Zhong J, Chen Y, Qiu X, Zhang T, Ma D, et al. Expression of chemokine-like factor 1 is upregulated during T lymphocyte activation. Life Sci 2006; 79:519–524. doi: 10.1016/j.lfs.2006.01.042.
doi: 10.1016/j.lfs.2006.01.042
Kim CH, Lim HW, Kim JR, Rott L, Hillsamer P, Butcher EC. Unique gene expression program of human germinal center T helper cells. Blood 2004; 104:1952–1960. doi: 10.1182/blood-2004-03-1206.
doi: 10.1182/blood-2004-03-1206
Carbone J, Gallego A, Lanio N, Navarro J, Orera M, Aguaron A, et al. Quantitative abnormalities of peripheral blood distinct T, B, and natural killer cell subsets and clinical findings in obstetric antiphospholipid syndrome. J Rheumatol 2009; 36:1217–1225. doi: 10.3899/jrheum.081079.
doi: 10.3899/jrheum.081079
Xu S, Tan JE, Wong EP, Manickam A, Ponniah S, Lam KP. B cell development and activation defects resulting in xid-like immunodeficiency in BLNK/SLP-65-deficient mice. Int Immunol 2000; 12:397–404. doi: 10.1093/intimm/12.3.397.
doi: 10.1093/intimm/12.3.397
Tan JE, Wong SC, Gan SK, Xu S, Lam KP. The adaptor protein BLNK is required for b cell antigen receptor-induced activation of nuclear factor-kappa B and cell cycle entry and survival of B lymphocytes. J Biol Chem 2001; 276:20055–20063. doi: 10.1074/jbc.M010800200.
doi: 10.1074/jbc.M010800200
Hayashi K, Nittono R, Okamoto N, Tsuji S, Hara Y, Goitsuka R, et al. The B cell-restricted adaptor BASH is required for normal development and antigen receptor-mediated activation of B cells. Proc Natl Acad Sci U S A 2000; 97:2755–2760. doi: 10.1073/pnas.040575697.
doi: 10.1073/pnas.040575697
Haas KM, Poe JC, Steeber DA, Tedder TF. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 2005; 23:7–18. doi: 10.1016/j.immuni.2005.04.011.
doi: 10.1016/j.immuni.2005.04.011
Martin F, Kearney JF. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a “natural immune memory”. Immunol Rev 2000; 175:70–79.
Velasquillo MC, Alcocer-Varela J, Alarcon-Segovia D, Cabiedes J, Sanchez-Guerrero J. Some patients with primary antiphospholipid syndrome have increased circulating CD5+ B cells that correlate with levels of IgM antiphospholipid antibodies. Clin Exp Rheumatol 1991; 9:501–505.
Zhang Y, Wang J, Han W. A role for CMTM7 in BCR expression and survival in B-1a but not B-2 cells. Int Immunol 2014; 26:47–57. doi: 10.1093/intimm/dxt042.
doi: 10.1093/intimm/dxt042
Liu Z, Liu Y, Li T, Wang P, Mo X, Lv P, et al. Cmtm7 knockout inhibits B-1a cell development at the transitional (TrB-1a) stage. Int Immunol 2019; 31:715–728. doi: 10.1093/intimm/dxz041.
doi: 10.1093/intimm/dxz041